Paper Details

  1. Home
  2. Paper Details

Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer.

Author: PapadimitrakopoulouVassiliki, RydénAnna, SebastianMartin, WaldingAndrew

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Patient-reported outcomes (PROs) using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) were analyzed in the AURA3 trial of osimertinib and chemotherapy for advanced non-small cell lung cancer. Diarrhea was more common with osimertinib, while fatigue and decreased appetite were less common. Nausea and vomiting were generally mild.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: In the AURA3 trial, individuals received osimertinib 80 mg once daily or chemotherapy for advanced non-small cell lung cancer. Here, we explore patient-reported symptoms possibly related to treatment. MATERIALS AND METHODS: AURA3 was an open-label, randomized phase III trial involving 4...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.lungcan.2018.05.003

データ提供：米国国立医学図書館（NLM）

Osimertinib vs. Chemotherapy: Patient-Reported Symptoms in Lung Cancer

Advanced non-small cell lung cancer (NSCLC) is a complex and challenging disease, often requiring aggressive therapies. This research explores the patient-reported symptoms associated with two different treatments for advanced NSCLC: osimertinib and chemotherapy. The authors meticulously analyzed data from patient-reported outcomes surveys, capturing the experiences of individuals undergoing these treatments. The study provides valuable insights into the potential side effects and overall impact of these treatments on patients' well-being. This research is a testament to the importance of patient-centered care, ensuring that treatment decisions are informed by the voices of those who experience them firsthand.

Osimertinib vs. Chemotherapy: A Patient’s Perspective

This study provides a patient-centered perspective on the experiences of individuals undergoing treatment for advanced NSCLC. It’s like listening to the stories of travelers who have traversed different paths through a vast desert: each journey has its unique challenges and rewards. The authors carefully analyze the reported symptoms, providing valuable insights into the lived experiences of patients undergoing these treatments.

Patient-Centered Care: A Journey of Understanding

This research emphasizes the importance of patient-centered care, listening to the voices of those who experience the effects of treatments firsthand. It’s like providing a map to those navigating a challenging desert landscape: by understanding their experiences, we can guide them toward safer and more effective journeys. This study encourages continued research and a focus on patient-reported outcomes to improve the care and support for individuals with advanced NSCLC.

Dr. Camel's Conclusion

This study provides a valuable glimpse into the patient-reported symptoms associated with osimertinib and chemotherapy for advanced NSCLC. It’s like listening to the whispers of the desert wind, revealing the personal stories and challenges faced by those navigating this complex and challenging disease. This study underscores the importance of incorporating patient-centered care into treatment decisions, ensuring that the voices of those who experience the effects of treatment are heard and respected.

Date :
  1. Date Completed 2019-06-28
  2. Date Revised 2022-06-03
Further Info :

Pubmed ID

30032816

DOI: Digital Object Identifier

10.1016/j.lungcan.2018.05.003

Related Literature

Article Analysis
・Side Effects of osimertinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.